IGF-1 DES

IGF-1 DES (Des(1-3)IGF-1) is a truncated form of insulin-like growth factor-1 lacking the first three N-terminal amino acids (glycine, proline, glutamate). This modification significantly alters the peptide's biological properties by dramatically reducing binding affinity to IGF binding proteins (IGFBPs). Since IGFBPs normally sequester and regulate IGF-1 activity, IGF-1 DES exhibits approximately 10-fold greater potency than native IGF-1 in stimulating cellular proliferation and protein synthesis. The truncated peptide acts primarily in an autocrine/paracrine fashion with rapid, potent local effects. Research demonstrates enhanced myogenic and mitogenic activity compared to standard IGF-1. IGF-1 DES has a very short half-life (20-30 minutes) due to rapid degradation, making it suitable for targeted local effects rather than systemic administration. The peptide is popular in research examining IGF-1 signaling and has been used experimentally for localized muscle growth applications. However, the enhanced potency also increases potential for adverse effects including hypoglycemia and must be used with appropriate caution.

All solid evidence is in-vitro (cell culture). No human or robust animal trials of IGF-1 DES exist; common claims about localized muscle growth, dosing, and a 20-30 minute half-life are not backed by published clinical or pharmacokinetic studies.

IGF-1 DES is des(1-3)IGF-1, an IGF-1 variant lacking the first three N-terminal amino acids; in cell studies its reduced IGFBP binding increases receptor availability. No approved human use, dose, or characterized human pharmacokinetics were found.